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Abstract
Background: Retinoic acid (RA) and fibroblast growth factor 4 (FGF4) signaling control endoderm patterning and pancreas
induction/expansion. Based on these findings, RA and FGFs, excluding FGF4, have frequently been used in differentiation
protocols to direct differentiation of hESCs into endodermal and pancreatic cell types. In vivo, these signaling pathways act
in a temporal and concentration-dependent manner. However, in vitro, the underlying basis for the time of addition of
growth and differentiation factors (GDFs), including RA and FGFs, as well as the concentration is lacking. Thus, in order to
develop robust and reliable differentiation protocols of ESCs into mature pancreatic cell types, including insulin-producing b
cells, it will be important to mechanistically understand each specification step. This includes differentiation of
mesendoderm/definitive endoderm into foregut endoderm- the origin of pancreatic endoderm.
Methodology/Principal Findings: Here, we provide data on the individual and combinatorial role of RA and FGF4 in
directing differentiation of ActivinA (AA)-induced hESCs into PDX1-expressing cells. FGF4’s ability to affect endoderm
patterning and specification in vitro has so far not been tested. By testing out the optimal concentration and timing of
addition of FGF4 and RA, we present a robust differentiation protocol that on average generates 32% PDX1
+ cells.
Furthermore, we show that RA is required for converting AA-induced hESCs into PDX1
+ cells, and that part of the underlying
mechanism involves FGF receptor signaling. Finally, further characterization of the PDX1
+ cells suggests that they represent
foregut endoderm not yet committed to pancreatic, posterior stomach, or duodenal endoderm.
Conclusion/Significance: In conclusion, we show that RA and FGF4 jointly direct differentiation of PDX1
+ foregut endoderm
in a robust and efficient manner. RA signaling mediated by the early induction of RARb through AA/Wnt3a is required for
PDX1 expression. Part of RA’s activity is mediated by FGF signaling.
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Introduction
To achieve the goal of creating a practical, replenishable source
of b cells for transplant therapy of patients with Type 1 diabetes, it
will be critical to understand the embryonic processes that
generate b cells, and to translate this knowledge into human
cellular systems.
Pancreatic b cells develop by progressive instructive differenti-
ation of pancreatic progenitors, which are derived as a result of the
regionalized differentiation of the definitive endoderm (DE).
Before any morphological signs of organogenesis are apparent in
the primitive gut tube, the endoderm becomes patterned through
the actions of a complex cross talk between mesoderm and
endoderm involving gradients of fibroblast growth factors (FGFs),
bone morphogenic proteins (BMPs), retinoic acid (RA), and sonic
hedgehog (SHH) [1–3]. Initially, the pancreas forms as a ventral
and a dorsal bud. The ventral bud is surrounded by cardiac
mesoderm and the dorsal bud is in contact with the notochord and
subsequently the dorsal aorta. Those are all mesodermally derived
tissues that influence formation of the pancreas [4,5].
Human embryonic stem cells (hESC) are derived from the inner
cell mass (ICM) of the blastocyst and have the potential to in vitro
follow the same developmental pathways as the ICM, including
differentiation into pancreatic cells [6]. Since the pancreas,
including the endocrine component, is derived from DE, there
have been focused efforts on in vitro induction of early
endodermal cell types. This approach has been taken in a number
of recent studies where knowledge of the signaling events that
orchestrate primitive streak (PS) formation, gastrulation, and
formation of DE during early mouse development has been
employed [7–9]. Although ESC-derived endoderm can be further
differentiated into more mature cell types, such as liver and
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pattern DE into posterior foregut endoderm and multipotent
pancreatic endoderm are lacking.
Retinaldehyde dehydrogenase (Raldh2), the enzyme responsible
for the biosynthesis of RA, is expressed in mesoderm during
gastrulation where it has been shown to pre-pattern the endoderm
and regulate early stages of pancreas development [14,15]. Raldh2
is also expressed in the mouse dorsal pancreatic mesenchyme at
the early stage of pancreas specification until E12.5 [16,17]. In
addition, RA acts as a posteriorizing agent in the gut endoderm. In
embryos with increased RA signaling, pancreas and liver fates
were expanded rostrally at the expense of anterior endoderm fates
such as thyroid and pharynx. Pancreas and liver specification
requires RA signaling, but more posterior endodermal organs do
not, implying a subdivision of the endoderm into RA-responsive
and non-responsive domains by late gastrulation. Several retinoic
acid receptors (RARs) exist of which RARb is the primary target
for RA [18]. RARs are ligand-activated transcription factors that
bind to retinoic acid response elements (RAREs) within the
promoter of their target genes. In embroid bodies (EBs) from
mESC, RA induces pancreatic duodenal homeobox 1 (PDX1/
IPF1)
+ pancreatic endoderm [12]. Pdx1 is a main regulator of
pancreas specification and b cell function [19–21]. RA is often
included in multi-factorial differentiation protocols towards
pancreatic cell types, albeit without defining its exact role.
Moreover, to our knowledge, the expression of RARs has not
been studied during differentiation of embryonic stem cells
towards DE and pancreatic cell types.
FGF4, which is expressed in the vicinity of the posterior
endoderm in the gastrula and early somite stage embryos, exhibit a
broad anterior-posterior patterning activity in the gut endoderm.
Specifically, FGF4 promotes posterior and inhibits anterior
endoderm cell fate [22]. FGF4 signals mainly via FGFR1c and
FGFR2c and to a smaller extent via FGFR3c and FGFR4 [23].
Importantly, moderate levels of FGF4 are needed to maintain
Pdx1 expression, whereas high levels of FGF4 repress Pdx1
expression. Thus, this data suggests that endoderm is patterned
by FGF4 both in a concentration and in a temporal dependent
manner and that the pancreas arise from cells that receive
intermediate levels of FGF4 [24]. Importantly, whether FGF4
affect ESC-derived DE in a similar manner remains unknown.
Other FGFs, such as FGF1 and FGF2 that are produced by the
cardiac mesoderm, are also involved in gut endoderm patterning,
albeit in a more restricted manner. These FGFs pattern the foregut
endoderm in a concentration-dependent manner, i.e. at lower
concentrations liver fate is promoted, whereas at higher concen-
trations lung fate is promoted [25].
Notably, RA and FGF signaling, which both exhibit endoder-
mal patterning activities and support pancreas specification, seem
to cross talk during these events [26]. For example, RAR is
required for the correct expression of fgf8, fgfr1 and fgfr4, and
addition of endogenous RA induces expression of fgf8, fgfr1 and
fgfr4 in animal cap experiments. Moreover, XCAD3 (the
equivalent of mammalian Cdx4) is a key downstream gene in the
FGF-mediated posteriorization pathway and retinoids are known
to influence the expression of caudal genes in other systems [27].
Here, we test the ability of RA and FGF4 alone and in
combination to direct differentiation of hESC-derived DE into
PDX1
+ posterior foregut endoderm. By optimizing the timing and
concentration of RA and FGF4, approximately 30% of all cells turn
into PDX1
+ foregut endoderm. Furthermore, RA is required for
differentiation into PDX1
+ cells and part ofits activity ismediated by
FGF signaling, suggesting cross talk between RA and FGF signaling
during RA-induced foregut specification from hESC.
Methods
Human embryonic stem cell culture
Routine culture. The hESC lines Hues-1, Hues-3 and Hues-
15 were obtained from D.A. Melton, Howard Hughes Medical
Institute (Harvard institute, Cambridge, MA) and cultured
according to protocols at http://mcb.harvard.edu/melton/hues/
as previously described [28]. Whereas the RA/FGF4 protocol was
tested on Hues-3 (subclone 52) and Hues-15, the D’Amour
protocol was tested on Hues-1 and Hues-3. The Cells were
maintained in KO-DMEM (Gibco) supplemented with 10% KO
serum replacement (Gibco), 1% Non-essential amino acids
(Gibco), 1% Glutamax (Gibco), 0.1% beta-mercaptoethanol
(Gibco), 1% penicillin-streptomycin (PEST) (Invitrogen), 10%
plasmanate (Talecris), and 10 ng/mL bFgf (Invitrogen). The
medium was changed daily to keep the cells in an undifferentiated
state. Cells were passaged with 0.05% trypsin-EDTA (Gibco)
every third or fourth day onto freshly seeded (25,000/cm
2)
mitotically inactivated mouse embryonic feeder-cells (MEFs)
(Sahlgrenska Akademin Experimental Biomedicine University of
Gothenburg) at a density of 12,000 cells/cm
2 for Hues-3 (subclone
52) and 30,000 cells/cm
2 for Hues-15. The cell lines were
karyotyped by standard G-banding by the Institute of Clinical
Genetics at the University of Linko ¨ping, Sweden. 12–23
metaphases were evaluated. Hues-1 and Hues-15 were found to
be karyotypically normal, whereas Hues-3 (subclone 52) has a gain
of material from chromosome 17 (82%).
Differentiation experiments. For differentiation experi-
ments, Hues-3 (subclone 52) cells were seeded at a density of
20,000 cells/cm
2 at passages 68–76, and cultured for three to four
days until a confluent flat layer of undifferentiated cells was
formed. Hues-15 cells were seeded at a density of 17,000 cells/
cm
2 at passage 23. At the start of each differentiation procedure at
high confluence of the cells, phosphate buffered saline (PBS)
(Gibco) was used to wash the cell layer once. The medium-
composition during the differentiation experiments is described in
Fig. 1A. Activin A (100 ng/mL) (R&D systems) and Wingless-type
MMTV integration site family, member 3A (Wnt3a) (25 ng/mL)
(R&D systems) was used to induce definitive endoderm (DE) in
Rosewell Park Memorial Intitute (RPMI) 1640 (Gibco)
supplemented with no fetal bovine serum (FBS) (Sigma) the first
day and 0.2% FBS the second and third day. As a control for DE-
induction, RPMI 1640 was used without addition of substances
other than FBS. At day four, samples were taken for real-time
polymerase chain reaction (PCR) analysis. On days four to seven,
RPMI 1640 was supplemented with 2% FBS and from day eight,
Dulbecco’s modified Eagle medium (DMEM) (Gibco) was used
supplemented with 2% FBS. From day four onward, Fibroblast
growth factor 4 (FGF4) (R&D systems), and Retinoic acid (RA)
(Sigma) were added in different combinations and concentrations
as described. On various different time-points, cyclopamine
(Sigma) was used in a concentration of 0.25 mM in order to
inhibit shh. Penicillin/Streptomycin (PEST) (1%) was added to
the differentiation medias. Non-treated (NT) cells did not get
addition of substances other than DE-induction. For the D’Amour
protocol, cells were treated as previously described [7]. When the
D’Amour protocol was tested on cell line Hues-1, cells died at
stage three representing the posterior foregut stage. However, with
cell line Hues-3, a small number of PDX1
+ cells was obtained at
stage three. Still, cells did not survive further treatment onto stage
four (pancreatic and endocrine precursors) or five (hormone
expressing endocrine cells) (data not shown). Brightfield images of
cells were taken on an inverted microscope (Eclipse TE2000-U)
(Nicon).
PDX1+ Foregut from hESCs
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Cells were harvested after trypsinization (0.05% Trypsin-
EDTA) and purified according to the protocol of GeneElute
Mammalian Total RNA Miniprep kit (Sigma). The mRNA
concentrations were determined by a NanoDrop ND-1000
spectrophotometer (Saveen Werner). The reverse transcription
was performed with SuperScript III (Invitrogen). Initially, mRNA
(50–500 ng), 2 mM random hexamers (Invitrogen), 2 mM Oligo
(dT) (Invitrogen), and 10 mM deoxynucleotidetriphosphates
(dNTP) (Fermentas) were incubated at 65uC for five minutes
followed by cooling down to 8uC. In the second step, 16First
Strand (FS) buffer (Invitrogen), 5 mM DTT (Invitrogen), 10 U
Superscript
TM III Reverse transcriptase (Invitrogen), and 2 U
RNaseOUT
TM (Invitrogen) was added to a final reaction volume
of 10 mL. The temperature profile of the reverse transcription
reaction was 25uC for five minutes, 50uC for 45 minutes, 55uC for
Figure 1. Overview of the different experiments leading up to conditions for obtaining PDX1-positive cells. (A) Medium compositions
in the differentiation procotol. (B) Optimal concentration of fibroblast growth factor 4 (FGF4) on days 4–7 in the presence of retinoic acid (RA) on
days 8–11. (C) mRNA expression of the retinoic acid receptor beta, RARb, after activin (AA) induction. (D) The impact of FGF4 and RA on relative PDX1
gene expression (Rel. Expr.) and cell amount. Abbreviations and concentrations used: AA=Activin A (100 ng/mL), Fgf4 (1.1 ng/mL) where not stated
otherwise, RA=Retinoic acid (2 mM), NT=no treatment after activin induction. (E) Immunofluorescence staining of Pdx1 using Pdx1-anti-goat
(1:1500) on day 13. Scale bars: E, 100 mm ; inset, 200 mm.
doi:10.1371/journal.pone.0004794.g001
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200 mL with water and stored in 220uC for later analysis by real-
time PCR.
Reverse transcription-polymerase chain reaction (RT-
PCR) analysis. Primers for RT-PCR were designed using
Primer 3 (http://www-genome.wi.mit.edu/cgi-bin/primer/
primer3_www.cgi) and are shown in Table 1. Assays for some
pancreatic progenitor markers, such as Ptf1a and Nkx6.1, were
designed and confirmed on human pancreatic tissue as a positive
control (data not shown). The pancreatic tissue was kindly
provided by O. Korsgren at the University of Uppsala, Sweden.
Human islets were used for cDNA-synthesis in order to analyse the
relative mRNA expression of PDX1 in islets compared to cells
differentiated according to the RA/FGF4-protocol on day 16.
Altogether, twelve RA/FGF4-treated samples from day 16 in
experiments 1–3 were compared to human islet cDNA. Real-time
PCR was carried out using the 7900HT Fast Real-time PCR
system (Applied biosystems). SYBR green was used as a double-
stranded DNA-specific fluorescent dye as detection chemistry in
the real-time PCR. Reactions were performed with the following
constituents: forward and reversed primers 400 nM, 16PlatinumH
Quantitative PCR superMix-UDG with ROX (Invitrogen),
0.1256SYBR (Invitrogen), and 3 mL template cDNA in 20 mL
reactions. The PCR was performed using the following settings:
Preincubation at 50uC for 2 min, and 95uC for 2 min followed by
45 cycles with denaturation at 95uC for 15 sec, annealing at 60uC
for 25 sec, and extension at 73uC for 30 sec. Cycle of threshold
(Ct)-values were determined using manual Ct and automatic
baseline. The correct PCR-product was confirmed by agarose gel
electrophoresis (2% w/v) and melting curve analysis. Data analysis
and relative quantification was performed as described [29,30],
using an overall PCR efficiency of 90%. Data was normalized
against ACTB. ACTB was verified as a suitable reference gene by
GeNorm [31]. The lowest value in each data set was arbitrarily set
to one and the rest of the data points were related to this value. In
cases where no gene expression was measured, as for some genes
of non-treated control cells, Ct values were set to 45, i.e. the
maxium amount of cycles run. Each experiment was performed
three times to confirm data. In each experiment, two to four
biological replicates were measured. In addition, duplicate
technical replicates were used throughout the measurements.
Mean values6SEM were calculated.
Immunocytochemistry. hESC were washed once with
phosphate-buffered saline (PBS) and then fixed for 15 minutes in
4% paraformaledehyde (PFA) (BDH) at room temperature
followed by an additional PBS wash. Cells were permeabilized
with 0.5% TritonX-100 (BDH) for 15 minutes, blocked in PBS
with 0.1% Tween (Research Organics) (PBS-T) supplemented
with 5% normal donkey serum (NDS) (Calbiochem) for one hour
at room temperature, and incubated with the primary antibody in
blocking buffer over night at 4uC. The following primary
antibodies were used: goat anti-Pdx1 (1:1500) and rabbit anti-
Table 1. Primer sequences used in RT-PCR.
Gene Forward primer sequence Reversed primer sequence
ACTB 59-CTGGAACGGTGAAGGTGACA-39 59- AAGGGACTTCCTGTAACAATGCA-39
PDX1 59-CCCATGGATGAAGTCTACC-39 59- GTCCTCCTCCTTTTTCCAC-39
SOX9 59-GAGGAAGTCGGTGAAGAACG-39 59-CCAACATCGAGACCTTCGAT-3
HNF6 59-CGGAGGATGTGGAAGTGG-39 59-TTTGGATGGACGCTTATTTTC-39
FOXA2 59-AGGAGGAAAACGGGAAAGAA-39 59-CAACAACAGCAATGGAGGAG-39
CDX2 59-ACCTGTGCGAGTGGATGC-39 59-TCCTTTGCTCTGCGGTTCT-39
CXCR4* 59-CACCGCATCTGGAGAACCA-39 59-GCCCATTTCCTCGGTCTAGTT-39
SOX17 59-AAGGGCGAGTCCCGTATC-39 59-TTGTAGTTGGGGTGGTCCTG-39
OCT4 59-CGAAAGAGAAAGCGAACCAG-39 59-AACCACACTCGGACCACATC-39
GSC 59-GAGGAGAAAGTGGAGGTCTGG-39 59- GCAAGAAAGTAGCATCGTCTG-39
FGFR2 59-TCCTGAGGAGCAGATGACCT-39 59-CCGAAGGACCAGACATCACT-39
FGFR1 59-GCCAGGACCCGAACAGAG-39 59-CCCAGAAGAGGAGGCACTT-39
RARb 59-ATGCTGGATTTGGTCCTCTG-39 59- TGCACCTTTAGCACTGATGC-39
FGF4 59-GACTACCTGCTGGGCATCAA-39 59- TGCACTCATCGGTGAAGAAG-39
PTF1a 59-GCCATCGGCTACATCAACTT-39 59- GGAGGGAGGCCATAATCAG-39
NGN3* 59-GCTCATCGCTCTCTATTCTTTTGC-39 59- GGTTGAGGCGTCATCCTTTCT-39
NKX6.1 59-ATTCGTTGGGGATGACAGAG-39 59-CGAGTCCTGCTTCTTCTTGG-39
ALB 59-GCAAGGCTGACGATAAGGAG-39 59-TGGCTTTACACCAACGAAAA-39
Raldh2 59-CACCATGACTTCCAGCAAGA-39 59-CAGGGAACACTCTCCCACTC-39
AFP 59-CTT TGG GCT GCT CGC TAT GA-39 59-TGG CTT GGA AAG TTC GGG TC-3
PROX1 59-TCACCTTATTCGGGAAGTGC-39 59-GTACTGGTGACCCCATCGTT-39
NKX2.2 59-TCTACGACAGCAGCGACAAC-39 59-GGGTCTCCTTGTCATTGTCC-39
NKX2.1 59-ACCAGGACACCATGAGGAAC-39 59-CGCCGACAGGTACTTCTGTT-39
GCG 59-AGAGGTCGCCATTGTTGAAG-39 59-GCAGGTGATGTTGTGAAGATG-39
INS* 59-AAGAGGCCATCAAGCAGATCA-39 59-CAGGAGGCGCATCCACA-39
Primer systems marked with an asterix were designed according to D’Amour et al. [7,33].
doi:10.1371/journal.pone.0004794.t001
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Medical Center, Nashville, USA), goat anti-FOXA2 (1:200)(Santa
Cruz) (a gift from P. Serup at the Hagedorn Institute, Gentofte,
Denmark), rabbit anti-HNF6 (1:30)(Santa Cruz), rabbit anti-
SOX9 (1:500) (Chemicon International), and rabbit anti-Phospho-
Histone H3 (1:400) (Upstate). The following day, cells were
washed once with PBS and then incubated for one hour at room
temperature in the dark with the secondary antibody in PBS-T,
washed once again, and then incubated with DAPI
(1:1000)(Sigma) for four minutes. The following secondary
antibodies were used: Cy3-a-rabbit (1:1000)(Jackson
ImmunoResearch), 488-a-goat (1:1000) (Molecular Probes/
Invitrogen). Images of immunofluorescently stained cells were
taken on a Nikon Eclipse TE 2000-U Axioplan 2 fluorescence
microscope and AxioVision LE software was used. Images were
edited in AdobeHPhotoshop version 8.0. For quantification of
PDX1-positive cells, cells in five different randomly chosen images
from two separate experiments were calculated. Based on these
calculations, an average value6SEM was determined.
Receptor inhibition. The FGF signaling was inhibited by
SU5402 (Calbiochem). SU5402 is a receptor tyrosine kinase
inhibitor functioning by competing for the ATP-binding site
within the catalytic domain of the receptor. SU5402 targets
vascular endothelial growth factor (VEGF) receptors and FGFR1.
However, since FGFRs are highly conserved, SU5402 is
considered to be a universal inhibitor of FGF signaling [32].
The RA signaling is antagonized by AGN193109, which was
synthesized by NovoNordisk and subsequently provided by the P.
Serup laboratory at the Hagedorn Institute, Gentofte, Denmark.
Cell viability assay
AlamarBlue
TM (Biosource) was used to assess cell viability
according to the protocol supplied.
Results
FGF4 and RA direct differentiation of PDX1
+ cells from
Activin A/Wnt3a-treated hESCs
The pivotal role of RA and FGF4 in endoderm and pancreas
development led us to investigate their role in directing
differentiation of putative DE, obtained through the frequently
used three-day Activin A/Wnt3a induction protocol [33] (AA-
induction) (Fig. S1 and S2), into PDX1
+ posterior foregut
endoderm. So far, FGF4 has not been tested for its activity in
patterning ESC-derived gut endoderm. In the absence of RA,
FGF4 was unable to induce PDX1 expression (data not shown).
Since it was previously shown that RA promotes differentiation
into PDX1
+ cells when added four days after the AA-induction [7],
we tested whether FGF4 synergized with RA in directing DE into
PDX1
+ cells. Indeed, PDX1 expression measured on day twelve
increased when FGF4 was added directly after AA-induction and
before the RA-treatment (Fig. 1B). Notably, FGF4 exhibited its
effect on PDX1 expression in a concentration-dependent manner.
Importantly, endogenous expression of FGF4 is only detected in
undifferentiated cells and not at later time-points (Fig. S3A). To
further optimize the protocol, the timing of RA addition was
considered. In fact, the timing of RA addition has in most previous
efforts been rather arbitrary, based on the fact that it should be
added rather soon after the DE-induction. Logically, the timing of
RA addition should be based on RARb expression, which so far
has not been determined. Therefore, we examined the timing of
RARb expression after AA-induction. Interestingly, RARb was
upregulated directly after the AA-induction on day four, and
subsequently downregulated (day eight) in the absence of any
exogenous growth and differentiation factor (GDF) (Fig. 1C and
5A; compare AA D4 with AA D8). Based on these findings we
then tested various combinations of FGF4 and RA to achieve
optimal induction of PDX1 expression during a twelve-day period
(Fig. 1D). Moreover, PDX1 expression increased at day 12 when
RA was added at day four compared to at day eight (Fig. S3B).
Further optimisation of the protocol revealed that the highest
PDX1-expression level was obtained when RA was kept through-
out the whole protocol, i.e. for 13 days after the activin induction.
Subtraction of RA at earlier time points (from day 10, 12 or 14)
diminished the relative expression of PDX1 (Fig. S3C). Yet further
prolonged treatment with RA and FGF4 still increases PDX1-
expression, but at this point cells could start to deteriorate,
probably due to high confluence. Notably, the marked increase in
cell number, but lack of effect on relative PDX1 expression, upon
addition of FGF4 (compare condition 3 with 2 in Fig. 1D) suggests
that FGF4 primarily affect cell survival. Moreover, the cell viability
assay AlamarBlue indicated that FGF4 promotes cell viability by
reducing cytotoxic effects possibly exhibited by RA (Fig. S3D).
Based on this observation we show that continuous treatment with
RA and FGF4 (1.1 ng/ml) after the AA-induction resulted in
efficient induction of PDX1 mRNA expression (,25-fold increase
in relative PDX1 mRNA expression on day 13; Fig. 1D).
Immunofluorescence analysis was used to confirm that the
observed increase in PDX1 mRNA expression was paralleled by
a significant increase at the protein level (Fig. 1E). It should be
noted that in cells that did not receive treatment with RA and
FGF4, no PDX1-protein was detected. Efforts were made to
passage the cells to new plates at this stage, but under currently
used experimental conditions the cells failed to survive this
treatment. The effect of RA and FGF4 was also evident by
changes in cell morphology. Treatment with RA and FGF4
resulted in smaller cells that often were assembled in small cell
clusters (Fig. 2).
To test the reproducibility of the combined action of RA and
FGF4 to direct differentiation of PDX1-expressing cells, we
repeated our protocol (Fig. 3A) three times using cell line Hues-
3 (subclone 52) at different passages. More specifically, passage 68,
75 and 76 were used. In order to get some relevant estimation of
the magnitude of PDX1-expression in differentiated hESC at day
16, the expression was compared to PDX1-expression in human
islets. PDX1-mRNA levels in differentiated hESC were approxi-
mately 50% of the levels detected in human islets (Fig. 3B). In
order to analyze the real-time PCR data, the lowest value of each
data set was set to one and all other values were related to this.
Following this procedure, a mean value was calculated for each of
the duplicate or triplicate samples. In some cases, the non-treated
cells did not have any measurable level of PDX1-transcripts
(Fig. 3C; Experiments 1 and 2) and consequently Ct-values were
set to 45. Moreover, to further establish the robustness of this
protocol, its cell line specificity was tested. For this purpose, the
RA/FGF4 protocol was tested on another hESC line: Hues-15
(Fig. S2). Indeed, RA/FGF4 effectively induced PDX1 expression
in Hues-15 (Fig. S2B). Thus, the fact that RA and FGF4
significantly increased PDX1 mRNA expression in Hues-15 and
Hues-3 subclone 52, suggests that the ability of these factors to
direct differentiation of AA-induced hESC into PDX1
+ cells is cell
line independent.
When the D’Amour protocol [7] was tested on cell line Hues-1,
cells died at stage three. However, with cell line Hues-3, a small
number of PDX1
+ cells was obtained at stage three. Still, cells did
not survive further treatment onto stage four and five (data not
shown). Importantly, these PDX1 expression levels were never as
high as with our RA/FGF4-protocol.
PDX1+ Foregut from hESCs
PLoS ONE | www.plosone.org 5 March 2009 | Volume 4 | Issue 3 | e4794Figure 2. Morphological appearance of cells at different stages of the FGF4/RA differentiation protocol. (A and A9) ‘‘Undiff.
D1’’=Undifferentiated cells at the start of experiment at day 1. (B and B9) Endoderm-like cells after Activin induction (AA) at day 4, (C and C9)
Untreated cells (ctrl=control) after Activin induction (AA) at day 16, (D and D9) Cells treated according to the Fgf4/RA differentiation protocol after
Activin induction (AA) at day 16. Scale bars: left column, 500 mm; right column, 100 mm.
doi:10.1371/journal.pone.0004794.g002
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foregut endoderm
In order to determine whether the induced PDX1
+ cells represents
posterior foregut pancreatic endoderm or non-pancreatic foregut
endoderm, the expression of markers characteristic for such cell
types were examined. Whereas the general gut endoderm marker
FOXA2 was expressed at high levels at all time points and unaffected
by RA/FGF4-treatment, the effect on expression of the midgut/
posterior gut endoderm marker CDX2 varied (Fig. 3B). Consistent
with the increase in PDX1 mRNA expression, a corresponding
increase in the transcription of the foregut endoderm markers HNF6
and SOX9 was observed (Fig. 3B). However, mRNA expression of
markers characteristic of posterior foregut pancreatic endoderm,
such as PTF1a and NKX6.1 was very low, suggesting that the
combined action of RA and FGF4 results in induction of PDX1
+
foregut endoderm. In addition, mRNA expression of NKX2.2,
NKX2.1, Glucagon (GCG) and Insulin (INS) was also very low or
undetectable. Thus, we speculate that the cells obtained with our
protocol represent multipotent foregut endoderm with the potential
to become pancreatic, posterior stomach, or duodenal endoderm.
Control cells, i.e. cells that subsequent to the AA-induction were
not treated with FGF4 and RA, adopted a hepatic fate as
determined by an upregulation of liver progenitor/hepatocyte
marker expression, including albumin, a-fetoprotein (AFP) and
prospero-related homeobox-1 (PROX1) (Fig. S4A).
To more directly examine the nature of the PDX1
+ cells,
immunofluorescence stainings with antibodies against gut endo-
derm, foregut endoderm, and posterior pancreatic foregut
endoderm were performed. All PDX1
+ cells, which primarily
were found in clusters, expressed FOXA2 (Fig. 4A). Furthermore,
a predominant fraction of the PDX1
+ cells co-expressed HNF6
and SOX9 (Fig 4A). Altogether, these data are consistent with the
Q-PCR data and supports the notion that FGF4 and RA
effectively direct differentiation of foregut endoderm.
Sonic hedgehog (Shh) signaling suppresses induction of a
pancreatic fate both in vivo and in vitro during ESC differentiation
[34–36]. However, preliminary results indicate that blocking SHH
signaling with cyclopamine at different time-points have no impact
on the appearance of PDX1
+ endoderm (data not shown). We also
investigated if RA had a direct downregulating effect on SHH,
which has been reported in Zebrafish studies [37,38]. However,
this was not the case.
PDX1
+ cells were quantified from five randomly chosen images
from two experiments. In each image, 2000–3000 cells were
analysed. Based on this analysis, the fraction of PDX1
+ was
estimated to be 32.5%63.7%. In addition, the PDX1
+ cells were
classified as low-expressing (17%) or high-expressing (15%) (Fig. 4B).
Notably, the levels of PDX1-expression showed no correlation with
the expression of any of the other examined endoderm markers.
Immunofluorescence detection of phospho-histone H3 demon-
strated that very few Pdx1
+ cells replicated on day sixteen of the
FGF4/RA protocol (Fig. S4B).
RA signaling is necessary for PDX1 induction
RA and FGF4 signaling coordinate anterior-posterior pattern-
ing of the gut endoderm [24,39,40]. Moreover, both RA and FGF
signaling is of key importance in induction of PDX1
+ cells in the
foregut endoderm [15,41]. Raldh2 is neither expressed by non-
treated cells nor by RA/FGF4-treated cells at any stage of the
protocol, suggesting that endogenous RA is not prevalent in this
system. This observation is consistent with the very low to
undetectable levels of PDX1 mRNA in non-treated control cells.
In order to begin to elucidate by which mechanism RA and FGF4
promote differentiation into PDX1
+ cells from hESCs, the temporal
expression pattern of FGFRs and RARb was examined. Interest-
ingly, RARb transcription was upregulated during the AA-
induction (day four), and maintained high in the presence of RA
until day eight, after which it declined (Fig. 5A). RA also affected
FGFR expression. In particular, FGFR2 expression was upregulated
by RA at day eight, after which it declined (Fig. 5A). To more
directly determine whether RA is required for PDX1 transcription,
the RA antagonist, AGN193109, was added during days four to
fifteen. Indeed, the RA antagonist completely blocked the RA-
induced PDX1 expression (Fig. 5B). The fact that blockage of
FGFR signaling (SU5402) in the presence of RA reduced relative
PDX1 mRNA expression at day nine, suggests that at least part of
RA’s stimulatory effects is mediated by FGF signaling. Thus, the
RA added in our protocol may allow FGF4 action by inducing
FGFR, although endogenous RA action in mouse embryos may
function by repressing FGF signaling. Blocking FGF signaling for
longer period compromised cell survival (data not shown).
Altogether, these data suggests that early RA signaling is required
for induction of PDX1 expression in AA-induced hESCs, and that
at least part of this activity can be explained by FGFR signaling.
Discussion
RA and FGF4 signaling control endoderm patterning and
pancreas induction/expansion in a temporal and concentration-
dependent manner in vivo. However, so far the combinatorial role
of these GDFs in differentiation of hESCs towards various gut
endoderm derivatives has not been tested. In addition, most
differentiation protocols towards pancreatic cell types do not
provide data on how the optimal concentration and timing of
individual GDFs were selected. Here, we provide data on the
individual and combinatorial role of RA and FGF4 in directing
differentiation of AA-induced hESCs into PDX1-expressing cells.
By testing out the optimal concentration and timing of adding
FGF4 and RA, we show for the first time that RA and FGF4 in a
dose-dependent manner synergistically induce differentiation into
PDX1
+ cells (on average 32%). In contrast to the in vivo situation,
FGF4 does not influence anterior-posterior patterning of the gut
endoderm, but promotes cell survival. Furthermore, we show that
RA is required for converting AA-induced hESCs into PDX1
+
cells, and that part of the underlying mechanism involves FGFR
signaling. Finally, further characterization of the PDX1
+ cells
suggests that they represent foregut endoderm. We speculate that
these cells represent multipotent foregut endoderm with the
potential to become pancreatic, posterior stomach, or duodenal
endoderm. Interestingly, activin-treated hESCs that spontaneously
differentiate in the absence of exogenous RA and FGF4 adopt a
liver fate, as assessed by the expression of AFP, Albumin and
PROX1.
Figure 3. Gene expression analysis of gut endodermal markers at day 16 using the FGF4/RA differentiation protocol. (A) The FGF4/
RA differentiation protocol. FBS=fetal bovine serum. Activin=Activin A 100 ng/mL, Wnt3a (25 ng/mL). (B) Relative mRNA expression of PDX1 in RA/
FGF4-treated hESC (Day 16) and human islets (C) Relative mRNA expression of PDX1, FOXA2, HNF6, SOX9, and CDX2 at day 12 and 16 with or without
(NT=no treatment) addition of RA and Fgf4 (F4) after AA-induction. In these experiments cell line Hues-3 (subclone 52) was used. In Experiment 1, NT
day 16 is missing.
doi:10.1371/journal.pone.0004794.g003
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PLoS ONE | www.plosone.org 9 March 2009 | Volume 4 | Issue 3 | e4794RA plays a prominent and conserved role in pancreas
specification [14–17,39]. Preceding pancreas formation, RA also
regulates pre-patterning of endoderm [15]. Consistent with these
findings, RA promotes differentiation of PDX1-expressing cells from
mESCs and hESCs [7–9,12]. The lack of data on the optimal timing
of adding RA to hESCs differentiating towards endodermal
derivatives led us to follow the expression-pattern of RARb.W e
show that the AA-induction upregulates RARb already at day four.
Consistently, we find that adding RA directly after the AA-induction
results in the most efficient induction of PDX1 expression.
Dessimoz et al. show that in chick studies, FGF4 induces posterior
endoderm markers in a concentration dependent manner and
inhibits expression of anterior endoderm markers, such as Hex1 and
Nkx2.1. Furthermore, they also demonstrate that moderate levels of
FGF4 maintain Pdx1 expression, whereas high levels of FGF4
signaling repress Pdx1 expression [24]. However, whether FGF4
exhibits the same activity on pluripotent stem cell-derived endoderm
in vitro remains unknown. Here, we tested the role of FGF4 alone
and in combination with RA in inducing PDX1 expression. FGF4
alone was unable to induce PDX1
+ cells from AA-induced hESCs
independentof theconcentration used andtime of addition (datanot
shown). Notably, FGF4 exhibited no posteriorizing effect on gut
endoderm as determined by markers characteristic for anterior and
posterior gut endoderm (data not shown). However, in combination
with RA, FGF4 promoted cell survival. Whether FGF4 exhibit
additional effects on cell differentiation remains to be determined.
Interestingly, the observation that blockage of FGF signaling in the
presence of RA reduced relative PDX1 mRNA expression is
consistent with such an activity.
Co-localization studies show that a fraction of FOXA2
+ cells co-
expressPDX1,butthatallPDX1
+cellsco-expressFOXA2.FOXA2
(HNF3b) is a member of the signaling nuclear factor-3/forkhead
family of transcription factors [42], which is expressed in foregut
endoderm and the derivatives thereof as well as in some ectodermal
and mesodermal tissues [43]. This observation suggests that all
PDX1
+ cells are of a foregut origin. Foxa2 is co-expressed with the
ONECUT transcription factor Hnf6 (Hepatocyte nuclear factor 6) in
the developing pancreatic epithelium [44]. In the mouse embryo,
Hnf6 is expressed in many tissues, among which the developing
pancreatic epithelium is one. Since Foxa2 expression is stimulated by
Hnf6, it has been proposed that Hnf6 is a key component in the
pancreatic transcription cascade. Moreover, Hnf6 regulates pancre-
atic endocrine cell differentiation and controls expression of the
proendocrine gene Ngn3 [45]. In addition, Hnf6 is required for
induction of Pdx1 expression in the ventral pancreatic bud but not in
the dorsal pancreatic bud [45,46]. We found HNF6 to be expressed
in the majority of PDX1
+ cells, supporting the notion that the
predominant fraction of PDX1
+ cells represents foregut endodermal
cells. The caudal related homeobox gene CDX2, which is expressed
in midgut, posterior gut endoderm as well as in trophectoderm [47],
was inconsistently regulated by RA/FGF4. SOX9 is an HMG-box
transcription factor that is expressed in multipotential pancreatic
progenitors and later in duct cells [48], stem cells and paneth cells of
the intestinal epithelium [49], neuronal cells [50,51], heart [52], and
hair [53]. In addition, SOX9 activates expression of the proendo-
crine marker Ngn3 and is required for the maintenance of the
pancreatic progenitor pool [48,54]. Moreover, in the developing
pancreas, expression of Sox9 is restricted to PDX1
+ progenitors and
is not found in committed endocrine precursors [48]. We found
SOX9 to be expressed in the majority of PDX1
+ cells. In conclusion,
co-localization data show that the RA/FGF4-induced PDX1
+ cells
co-express FOXA2, HNF6, and SOX9, representing foregut
endoderm. However, although these markers are expressed in
multipotent pancreatic endoderm, their expression in the non-
pancreatic foregut endoderm precludes judgement of a pancreatic
endodermal phenotype. In order to evaluate whether any of the
PDX1
+ cells represents pancreatic endoderm, expression of PTF1a
(PTF1/p48) and NKX6.1 were examined. PTF1a is a member of the
basic helix-loop-helix (bHLH) transcription factor family that, in
addition to being expressed in non-endodermal cell types such as
various neuronal precursor cells [55–57], is specifically expressed in
the early pancreatic endoderm within the foregut endoderm. PTF1a
is required for exocrine cell differentiation, and lineage-tracing
studies show that Ptf1a-expressing cells give rise to all pancreatic cell
lineages [58,59]. NKX6.1, a member of the NK homeodomain
transcription factor family, is expressed during mouse fetal
development in the majority of pancreatic epithelial cells from the
earliest stage of bud formation at E9.5 until the onset of the
secondary transition at E13.5 [60]. Thus, PDX1
+ cells co-expressing
PTF1a and NKX6.1 is diagnostic for pancreatic endoderm.
However, quantitative analysis of PTF1a and NKX6.1 mRNA
expression revealed no, to very low, levels of these mRNAs.
Consistently,expression ofNKX6.1 protein was undetectable. Thus,
in conclusion, the PDX1
+ cells induced by the RA/FGF4 protocol
represent either posterior stomach/duodenal endoderm, or pre-
pancreatic posterior foregut endoderm not yet expressing genes
representative of pancreatic foregut endoderm.
Multiple points of interactions exist between RA and FGF
signaling during embryonic axis formation in Xenopus [27] and
mouse [26]. The temporally regulated and distinct expression
patterns of RARb and FGFR1/FGFR2 led us to test whether RA
signaling regulated FGFR1/FGFR2 expression and vice versa.
However, blocking FGF signaling had no impact on RARb
expression and blocking RA receptors had no impact on FGFRs
(data not shown). Interestingly, blocking FGF signaling concom-
itant with RA treatment resulted in reduced relative PDX1 mRNA
expression, supporting the notion that at least part of RA’s
inductive effect on PDX1 expression is mediated by FGF signaling.
Thus, RA acts partly independent of, and partly synergistically
with, FGF signaling in directing differentiation of hESCs into
PDX1
+ foregut endoderm.
In conclusion, we show that RA and FGF4 jointly direct
differentiation of PDX1
+ foregut endoderm in a robust and
efficient manner. RA signaling mediated by the early induction of
RARb through AA/Wnt3a is required for PDX1 expression. Part
of RA’s activity is mediated by FGF signaling. The differentiation
protocol yields on average 32% PDX1-expressing cells represent-
ing foregut endoderm. We speculate that these cells represent
multipotent foregut endoderm with the potential to become
pancreatic, posterior stomach, or duodenal endoderm.
Supporting Information
Figure S1 Gene expression analysis of Activin (AA) induction
using cell line HUES-3 (Subclone 52).(A) The induction protocol.
Wnt, Wnt3a; FGF4, Fibroblast growth factor 4; FBS, fetal bovine
Figure 4. Characterization of PDX1
+ cells generated by the Fgf4/RA differentiation protocol on day 16. (A) Immunofluorescence
stainings of PDX1, SOX9, FOXA2, and HNF6. Nuclei are indicated by DAPI staining. Scale bars: 100 mm. (B) Quantification of the total amount of PDX1-
positive cells on day 16 (bar chart) and low and high-intensity PDX1-positive cells (pie chart). A cell representative of high PDX1-expression is
indicated by an arrow and of low PDX1-level by an arrow head. Scale bar: 10 mm.
doi:10.1371/journal.pone.0004794.g004
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PLoS ONE | www.plosone.org 10 March 2009 | Volume 4 | Issue 3 | e4794Figure 5. Analysis of expression and role of FGF and RA receptors during the FGF4/RA differentiation protocol. (A) Relative mRNA
expression of PDX1, fibroblast growth factor receptors 1 and 2 (FGFR1, FGFR2), and retinoic acid receptor beta (RARb) on different days (D1–D16)
during the induction. RA, retinoic acid; F4, fibroblast growth factor 4. Cells were always pretreated with Activin-A (AA)-induction for three days. (B)
Pharmacological inhibition of FGF (SU)- and RA (AGN)-receptor signaling on day nine of the FGF4/RA differentiation protocol. SU, SU5402 at 5 ng/mL;
AGN, AGN193109 at 1 mM; 0=no addition of any substance; AA, activin A; AA0, AA the first three days followed by no addition of FGF4/RA. Data is
based on three separate experiments with cell line Hues-3 (subclone 52).
doi:10.1371/journal.pone.0004794.g005
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PLoS ONE | www.plosone.org 11 March 2009 | Volume 4 | Issue 3 | e4794serum. (B) Relative mRNA expression of CXCR4, goosecoid
(GSC), SOX17 and OCT4 at day one (Start) and four (after AA-
induction).
Found at: doi:10.1371/journal.pone.0004794.s001 (0.32 MB
DOC)
Figure S2 Gene expression analysis of the FGF4/RA differen-
tiation protocol at day 16 using cell line HUES-15. (A) Relative
mRNA expression of CXCR4, goosecoid (GSC), SOX17 and
OCT4 at day one (Start) and four (after AA-induction). (B)
Relative expression of PDX1, FOXA2, HNF6, SOX9, and CDX2
at day 12 C (control, no RA/FGF4), 12, and 16.
Found at: doi:10.1371/journal.pone.0004794.s002 (0.13 MB
DOC)
Figure S3 Endogenous expression of FGF4, early and late
requirements of RA and cellular respiration after various RA/
FGF4-treatments. (A) Relative expression levels of endogenous
FGF4 during the RA/FGF4-differentiation protocol. A=Activin
A, RA=retinoic acid, F4=Fibroblast growth factor 4. (B) Initial
requirement of RA. Relative expression of PDX1 after various
combinations of RA and F4 from day 4–11. NT=No Treatment.
(C) Late requirement of RA. Relative expression of PDX1 after
various combinations of RA and F4 from day 4–15. (D) The
AlamarBlue assay determines cellular respiration. Fluorescence
after various RA/F4-treatments.
Found at: doi:10.1371/journal.pone.0004794.s003 (0.48 MB
DOC)
Figure S4 Gene expression profile of some liver markers and few
proliferating PDX1 cells using the RA/FGF4-differentiation
protocol. (A) Relative expression levels of albumin (ALB), a-
fetoprotein (AFP), and prospero-related homeobox 1 (PROX1) in
non-treated (NT) and RA/FGF4 (RA F4)-treated cells. RA=R-
etinoic acid, F4=Fibroblast growth factor 4. Measurements from
experiment three are shown. (B) Proliferating cells in mitotic phase
indicated by PH3 (phosphor-histone 3)- staining on day 16 of the
RA/FGF4-protocol. Arrowheads show PH3/PDX1 double-posi-
tive cells. Scale bar: 100 mm.
Found at: doi:10.1371/journal.pone.0004794.s004 (1.31 MB
DOC)
Acknowledgments
We are grateful to D.A. Melton for providing hESC lines. We would like to
thank Drs. Grapin-Botton, Serup, Wright for advice and supply of
reagents. We thank Prof. Olle Korsgren for providing human islets, via the
Nordic Network for Clinical Islet Transplantation, Uppsala University,
Sweden. All procedures involving human islet material were approved by
ethical committees at Uppsala and Lund Universities. In addition, we
thank Dr. Maria Hammarstedt, Ann-Katrin Ha ¨ger, Karolina Landerman,
Ingrid Sandelin, and Ingar Nilsson for excellent technical assistance. We
also thank Dr. Yvonne Fischer for comments on the manuscript.
Author Contributions
Conceived and designed the experiments: MMJ AS HS. Performed the
experiments: MMJ AS JA FWS KN. Analyzed the data: MMJ AS JA FWS
KN HS. Contributed reagents/materials/analysis tools: MMJ HS. Wrote
the paper: MMJ HS.
References
1. Zaret KS (2001) Hepatocyte differentiation: from the endoderm and beyond.
Curr Opin Genet Dev 11: 568–574.
2. Shannon JM, Hyatt BA (2004) Epithelial-mesenchymal interactions in the
developing lung. Annu Rev Physiol 66: 625–645.
3. Cardoso WV, Lu J (2006) Regulation of early lung morphogenesis: questions,
facts and controversies. Development 133: 1611–1624.
4. Kim SKaH, M (2001) Intercellular signals regulating pancreas development and
function. Genes and development 15: 111–127.
5. Kim SKaM, RJ (2002) Signaling and transcriptional control of pancreatic
organogenesis. Current opinion in genetics and development 12: 540–547.
6. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ,
Marchall VS, Jones JM (1998) Embryonic stem cell lines derived from human
blastocysts. science 282: 1145–1430.
7. D’Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, et al. (2006)
Production of pancreatic hormone-expressing endocrine cells from human
embryonic stem cells. Nat Biotechnol 24: 1392–1401.
8. Jiang J, Au M, Lu K, Eshpeter A, Korbutt G, et al. (2007) Generation of insulin-
producing islet-like clusters from human embryonic stem cells. Stem Cells 25:
1940–1953.
9. Shiraki N, Yoshida T, Araki K, Umezawa A, Higuchi Y, et al. (2008) Guided
differentiation of embryonic stem cells into Pdx1-expressing regional-specific
definitive endoderm. Stem Cells 26: 874–885.
10. Cai J, Zhao Y, Liu Y, Ye F, Song Z, et al. (2007) Directed differentiation of
human embryonic stem cells into functional hepatic cells. Hepatology 45:
1229–1239.
11. Spence JR, Wells JM (2007) Translational embryology: using embryonic
principles to generate pancreatic endocrine cells from embryonic stem cells. Dev
Dyn 236: 3218–3227.
12. Micallef SJ, Janes ME, Knezevic K, Davis RP, Elefanty AG, et al. (2005)
Retinoic acid induces Pdx1-positive endoderm in differentiating mouse
embryonic stem cells. Diabetes 54: 301–305.
13. Frandsen U, Porneki AD, Floridon C, Abdallah BM, Kassem M (2007) Activin
B mediated induction of Pdx1 in human embryonic stem cell derived embryoid
bodies. Biochem Biophys Res Commun 362: 568–574.
14. Stafford D, Prince VE (2002) Retinoic acid signaling is required for a critical
early step in zebrafish pancreatic development. Curr Biol 12: 1215–1220.
15. Chen Y, Pan FC, Brandes N, Afelik S, Solter M, et al. (2004) Retinoic acid
signaling is essential for pancreas development and promotes endocrine at the
expense of exocrine cell differentiation in Xenopus. Dev Biol 271: 144–160.
16. Martin M, Gallego-Llamas J, Ribes V, Kedinger M, Niederreither K, et al.
(2005) Dorsal pancreas agenesis in retinoic acid-deficient Raldh2 mutant mice.
Dev Biol 284: 399–411.
17. Molotkov A, Molotkova N, Duester G (2005) Retinoic acid generated by Raldh2
in mesoderm is required for mouse dorsal endodermal pancreas development.
Dev Dyn 232: 950–957.
18. deTheH,MarchioA,TiollaisP,DejeanA(1989)Differentialexpressionandligand
regulation of the retinoic acid receptor alpha and beta genes. Embo J 8: 429–433.
19. Jonsson J, Carlsson L, Edlund T, Edlund H (1994) Insulin-promoter-factor 1 is
required for pancreas development in mice. Nature 371: 606–609.
20. Offield MF, Jetton TL, Labosky PA, Ray M, Stein RW, Magnusson MA,
Hogan BLM, Wright VE (1996) PDX-1 is required fo pancreatic outgrowth and
differentiation of the rostral duodenum. Development 122: 983–995.
21. Murtaugh LCaM, DA (2003) Genes, signals, and lingeages in pancreas
development. Annu Rev Cell Dev Biol 19: 71–89.
22. Wells JM, Melton DA (2000) Early mouse endoderm is patterned by soluble
factors from adjacent germ layers. Development 127: 1563–1572.
23. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, et al. (2006)
Receptor specificity of the fibroblast growth factor family. The complete
mammalian FGF family. J Biol Chem 281: 15694–15700.
24. Dessimoz J, Opoka R, Kordich JJ, Grapin-Botton A, Wells JM (2006) FGF
signaling is necessary for establishing gut tube domains along the anterior-
posterior axis in vivo. Mech Dev 123: 42–55.
25. Serls AE, Doherty S, Parvatiyar P, Wells JM, Deutsch GH (2005) Different
thresholds of fibroblast growth factors pattern the ventral foregut into liver and
lung. Development 132: 35–47.
26. Duester G (2008) Retinoic acid synthesis and signaling during early
organogenesis. Cell 134: 921–931.
27. Shiotsugu J, Katsuyama Y, Arima K, Baxter A, Koide T, et al. (2004) Multiple
points of interaction between retinoic acid and FGF signaling during embryonic
axis formation. Development 131: 2653–2667.
28. Cowan CA, Klimanskaya I, McMahon J, Atlenza J, Witmyer J, Zucker JP,
Wang SW, Morton CC, McMahon AP, Powers D, Melton DA (2004)
Derivation of embryonic stem-cell lines from human blastocysts. The new
England journal of medicine 350: (13) 1353–6.
29. Stahlberg A, Zoric N, Aman P, Kubista M (2005) Quantitative real-time PCR
for cancer detection: the lymphoma case. Expert Rev Mol Diagn 5: 221–230.
30. Bustin SA (2002) Quantification of mRNA using real-time reverse transcription
PCR (RT-PCR): trends and problems. J Mol Endocrinol 29: 23–39.
31. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002)
Accurate normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
32. Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC (2004) Targeting
FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and
PD173074. Leukemia 18: 962–966.
PDX1+ Foregut from hESCs
PLoS ONE | www.plosone.org 12 March 2009 | Volume 4 | Issue 3 | e479433. D’Amour KA, Agulnick AD, Eliazer S, Kelly OG, Kroon E, et al. (2005)
Efficient differentiation of human embryonic stem cells to definitive endoderm.
Nat Biotechnol 23: 1534–1541.
34. Apelqvist A, Ahlgren U, Edlund H (1997) Sonic hedgehog directs specialised
mesoderm differentiation in the intestine and pancreas. Curr Biol 7: 801–804.
35. Hebrok M, Kim SK, St Jacques B, McMahon AP, Melton DA (2000)
Regulation of pancreas development by hedgehog signaling. Development 127:
4905–4913.
36. Kim SK, Melton DA (1998) Pancreas development is promoted by cyclopamine,
a hedgehog signaling inhibitor. Proc Natl Acad Sci U S A 95: 13036–13041.
37. Hoffman L, Miles J, Avaron F, Laforest L, Akimenko MA (2002) Exogenous
retinoic acid induces a stage-specific, transient and progressive extension of
Sonic hedgehog expression across the pectoral fin bud of zebrafish. Int J Dev
Biol 46: 949–956.
38. Laforest L, Brown CW, Poleo G, Geraudie J, Tada M, et al. (1998) Involvement
of the sonic hedgehog, patched 1 and bmp2 genes in patterning of the zebrafish
dermal fin rays. Development 125: 4175–4184.
39. Wang Z, Dolle P, Cardoso WV, Niederreither K (2006) Retinoic acid regulates
morphogenesis and patterning of posterior foregut derivatives. Dev Biol 297:
433–445.
40. Kumar M, Jordan N, Melton D, Grapin-Botton A (2003) Signals from lateral
plate mesoderm instruct endoderm toward a pancreatic fate. Dev Biol 259:
109–122.
41. Deutsch G, Jung J, Zheng M, Lora J, Zaret KS (2001) A bipotential precursor
population for pancreas and liver within the embryonic endoderm. Development
128: 871–881.
42. Costa M, Dottori M, Sourris K, Jamshidi P, Hatzistavrou T, et al. (2007) A
method for genetic modification of human embryonic stem cells using
electroporation. Nat Protoc 2: 792–796.
43. Besnard V, Wert SE, Hull WM, Whitsett JA (2004) Immunohistochemical
localization of Foxa1 and Foxa2 in mouse embryos and adult tissues. Gene Expr
Patterns 5: 193–208.
44. Rausa F, Samadani U, Ye H, Lim L, Fletcher CF, et al. (1997) The cut-
homeodomain transcriptional activator HNF-6 is coexpressed with its target
gene HNF-3 beta in the developing murine liver and pancreas. Dev Biol 192:
228–246.
45. Jacquemin P, Durviaux SM, Jensen J, Godfraind C, Gradwohl G, et al. (2000)
Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine
cell differentiation and controls expression of the proendocrine gene ngn3. Mol
Cell Biol 20: 4445–4454.
46. Wilding L, Gannon M (2004) The role of pdx1 and HNF6 in proliferation and
differentiation of endocrine precursors. Diabetes Metab Res Rev 20: 114–123.
47. Tolkunova E, Cavaleri F, Eckardt S, Reinbold R, Christenson LK, et al. (2006)
The caudal-related protein cdx2 promotes trophoblast differentiation of mouse
embryonic stem cells. Stem Cells 24: 139–144.
48. Seymour PA, Freude KK, Tran MN, Mayes EE, Jensen J, et al. (2007) SOX9 is
required for maintenance of the pancreatic progenitor cell pool. Proc Natl Acad
Sci U S A 104: 1865–1870.
49. Blache P, van de Wetering M, Duluc I, Domon C, Berta P, et al. (2004) SOX9 is
an intestine crypt transcription factor, is regulated by the Wnt pathway, and
represses the CDX2 and MUC2 genes. J Cell Biol 166: 37–47.
50. Spokony RF, Aoki Y, Saint-Germain N, Magner-Fink E, Saint-Jeannet JP (2002)
The transcription factor Sox9 is required for cranial neural crest development in
Xenopus. Development 129: 421–432.
51. Stolt CC, Lommes P, Sock E, Chaboissier MC, Schedl A, et al. (2003) The Sox9
transcription factor determines glial fate choice in the developing spinal cord.
Genes Dev 17: 1677–1689.
52. Akiyama H, Chaboissier MC, Behringer RR, Rowitch DH, Schedl A, et al.
(2004) Essential role of Sox9 in the pathway that controls formation of cardiac
valves and septa. Proc Natl Acad Sci U S A 101: 6502–6507.
53. Vidal VP, Chaboissier MC, Lutzkendorf S, Cotsarelis G, Mill P, et al. (2005)
Sox9 is essential for outer root sheath differentiation and the formation of the
hair stem cell compartment. Curr Biol 15: 1340–1351.
54. Lynn FC, Smith SB, Wilson ME, Yang KY, Nekrep N, et al. (2007) Sox9
coordinates a transcriptional network in pancreatic progenitor cells. Proc Natl
Acad Sci U S A 104: 10500–10505.
55. Glasgow SM, Henke RM, Macdonald RJ, Wright CV, Johnson JE (2005) Ptf1a
determines GABAergic over glutamatergic neuronal cell fate in the spinal cord
dorsal horn. Development 132: 5461–5469.
56. Fujitani Y, Fujitani S, Luo H, Qiu F, Burlison J, et al. (2006) Ptf1a determines
horizontal and amacrine cell fates during mouse retinal development.
Development 133: 4439–4450.
57. Hoshino M, Nakamura S, Mori K, Kawauchi T, Terao M, et al. (2005) Ptf1a, a
bHLH transcriptional gene, defines GABAergic neuronal fates in cerebellum.
Neuron 47: 201–213.
58. Kawaguchi Y, Cooper B, Gannon M, Ray M, MacDonald RJ, et al. (2002) The
role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic
progenitors. Nat Genet 32: 128–134.
59. Zhou Q, Law AC, Rajagopal J, Anderson WJ, Gray PA, et al. (2007) A
multipotent progenitor domain guides pancreatic organogenesis. Dev Cell 13:
103–114.
60. Pedersen JK, Nelson SB, Jorgensen MC, Henseleit KD, Fujitani Y, et al. (2005)
Endodermal expression of Nkx6 genes depends differentially on Pdx1. Dev Biol
288: 487–501.
PDX1+ Foregut from hESCs
PLoS ONE | www.plosone.org 13 March 2009 | Volume 4 | Issue 3 | e4794